This is a synthetic analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin.

Indications: advanced prostate cancer; endometriosis; precocious puberty, reduction in size of uterine fibrosis.

Cautions: Men at risk of tumour ‘flare’ should be monitored closely during first month of therapy. In patients with bone disease because reduction in bone mineral density can occur. The injection site should be rotated.

Side effect: Transient hypertension, dry mouth, paraesthesia, increased dysuria, gynaecomastia.

Dose: advanced prostate cancer: 3mg every 4 weeks. Endometriosis and reduction in uterine fibroids: 3mg every 4 weeks starting during first 5 days of menstrual cycle. Max. duration of treatment – 6 months.